ArticleRSC advances2022
Exploring novel heterojunctions based on the cerium metal-organic framework family and CAU-1, as dissimilar structures, for the sake of photocatalytic activity enhancement.
Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Copper Foam-Supported Ce-MOF-808-On-SNW‑1 for Efficient Pararosaniline Photodegradation: A Novel MOF-On-COF/Substrate Coating Strategy.ACS omega · 2025Article
- Optimization of cerium-based metal-organic framework synthesis for maximal sonophotocatalytic tetracycline degradation.Scientific reports · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ce-based metal-organic frameworks (Ce-MOFs) are excellent photocatalysts due to their high efficiency in charge transportation. The integration of this family with CAU-1 (CAU standing for Christian-Albrechts-University), as a MOF benefiting from its ultra-high surface area, can remarkably enhance the properties of the structure. This research includes four new heterojunctions, namely CAU-1/Ce-BDC-NH
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.